Bristol-Myers SquibbBMY
BMY
About: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Employees: 34,100
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
225% more first-time investments, than exits
New positions opened: 345 | Existing positions closed: 106
50% more funds holding in top 10
Funds holding in top 10: 26 [Q3] → 39 (+13) [Q4]
17% more capital invested
Capital invested by funds: $77.9B [Q3] → $91.4B (+$13.5B) [Q4]
9% more funds holding
Funds holding: 2,225 [Q3] → 2,420 (+195) [Q4]
4.02% more ownership
Funds ownership: 74.39% [Q3] → 78.41% (+4.02%) [Q4]
1% more repeat investments, than reductions
Existing positions increased: 911 | Existing positions reduced: 899
0% more call options, than puts
Call options by funds: $1.75B | Put options by funds: $1.75B
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$54
12%
upside
Avg. target
$60
24%
upside
High target
$68
41%
upside
8 analyst ratings
2 positive
25%
6 neutral
75%
0 negative
0%
Cantor Fitzgerald Carter Gould 22% 1-year accuracy 7 / 32 met price target | 14%upside $55 | Neutral Reiterated | 23 Apr 2025 |
Jefferies Akash Tewari 10% 1-year accuracy 1 / 10 met price target | 41%upside $68 | Buy Maintained | 23 Apr 2025 |
Piper Sandler David Amsellem 39% 1-year accuracy 13 / 33 met price target | 35%upside $65 | Overweight Initiated | 22 Apr 2025 |
UBS Trung Huynh 13% 1-year accuracy 1 / 8 met price target | 12%upside $54 | Neutral Maintained | 11 Apr 2025 |
Goldman Sachs Asad Haider 100% 1-year accuracy 2 / 2 met price target | 14%upside $55 | Neutral Downgraded | 8 Apr 2025 |
Financial journalist opinion
Based on 63 articles about BMY published over the past 30 days
Positive
Zacks Investment Research
1 hour ago
Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.80 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to loss of $4.40 per share a year ago.
Positive
Barrons
3 hours ago
Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance
Bristol Myers sees revenue decline in its legacy drug portfolio due to competition and Medicare headwinds.
Positive
Reuters
3 hours ago
Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales
Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's own immune system to fight cancer.
Positive
CNBC
3 hours ago
Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs
Bristol Myers Squibb beat first-quarter estimates and hiked its revenue and profit guidance for the year, as the drugmaker cuts costs. The company said its guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not President Donald Trump's planned duties on pharmaceuticals imported into the U.S.
Neutral
Business Wire
3 hours ago
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports First Quarter Financial Results for 2025.
Negative
Benzinga
1 day ago
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Bristol Myers Squibb & Co BMY on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia.
Negative
Barrons
1 day ago
Bristol Myers Stock Falls After Drug Trial Setback. Why 1 Analyst Isn't Worried.
Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said in a statement.
Neutral
Investors Business Daily
1 day ago
Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test
Shares of Bristol Myers Squibb tumbled late Tuesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study.
Negative
Reuters
1 day ago
Bristol Myers' Cobenfy fails to meet main goal as add-on treatment for schizophrenia
Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference compared to a placebo in a late-stage trial studying it as a add-on treatment for schizophrenia.
Neutral
Business Wire
1 day ago
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ARISE--BMS Announces Topline Results from Phase 3 ARISE Trial.
Charts implemented using Lightweight Charts™